Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,321 papers from all fields of science
Search
Sign In
Create Free Account
Complete Hematologic Response
Known as:
CHR
The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Clinical Data Interchange Standards Consortium Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study
T. Brümmendorf
,
H. Kantarjian
,
+9 authors
J. Cortes
2012
Corpus ID: 79469452
Abstract 69 Bosutinib (BOS) is an oral, dual Src/Abl kinase inhibitor. In the randomized, phase 3 BELA trial, BOS 500 mg/d…
Expand
Review
2010
Review
2010
Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Matthew P Wright
,
J. Shepherd
,
+11 authors
D. Forrest
Biology of Blood and Marrow Transplantation
2010
Corpus ID: 25190816
2009
2009
Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation
S. Merante
,
Anna Amelia Colombo
,
+6 authors
E. Alessandrino
Bone Marrow Transplantation
2009
Corpus ID: 28758355
Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic…
Expand
2009
2009
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients…
C. Fava
,
H. Kantarjian
,
+9 authors
J. Cortes
Blood
2009
Corpus ID: 206875053
Second-generation tyrosine kinase inhibitors are effective in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic…
Expand
2009
2009
Complexity of BCR‐ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia
D. Verma
,
C. Fava
,
H. Kantarjian
,
J. Cortes
American journal of hematology/oncology
2009
Corpus ID: 29524230
The most common mechanism of acquired resistance in CML in imatinib era is the acquisition of BCR-ABL kinase domain mutations…
Expand
Review
2007
Review
2007
Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance
S. Sohn
,
J. Moon
,
+5 authors
Soo‐Ok Kim
Leukemia and Lymphoma
2007
Corpus ID: 37347175
Recently, increasing the dosage of imatinib mesylate (IM) has been suggested as a method for overcoming IM resistance in CML…
Expand
Highly Cited
2006
Highly Cited
2006
Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study.
B. Druker
,
F. Guilhot
,
S. O’Brien
,
R. Larson
Journal of Clinical Oncology
2006
Corpus ID: 8104008
6506 Background: IM was proven to be superior to IFN+Ara-C for newly diagnosed patients (pts) with CML-CP (O' Brien et al, NEJM…
Expand
2005
2005
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
R. Saba
,
E. Jabbour
,
+7 authors
S. Verstovsek
Cancer
2005
Corpus ID: 21802792
BACKGROUND In 1986, a Phase II trial of recombinant interferon-alpha (IFN-alpha) was initiated as therapy for patients with…
Expand
Review
2003
Review
2003
Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission
S. Wilde
,
Katrina Rack
,
P. Vannuffel
,
A. Delannoy
,
A. Hagemeijer
Leukemia
2003
Corpus ID: 32637806
Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic…
Expand
1981
1981
Hairy cell leukemia: clinical effects of the methanol extraction residue (MER) of BCG, lithium carbonate and mononuclear cell-enriched leukocyte transfusions.
J. Quesada
,
E. Hersh
,
M. Keating
,
A. Zander
,
J. Hester
Leukemia research : a Forum for Studies on…
1981
Corpus ID: 40426186
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE